Delivery Order SPE2DB22D1103-SPE2DB25FH2X7
- Not listed
- The Defense Logistics Agency awarded a $25,556.44 delivery order to AmerisourceBergen Drug Corp for Attruby 356 mg tablets (quantity: 28 units) on September 11, 2025, with an ultimate completion date of October 2, 2025. This competitively awarded, non-set-aside contract utilizes firm fixed pricing and represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 through December 2026. The pharmaceutical...
- The Defense Logistics Agency awarded a $12,778.22 firm fixed price delivery order to AmerisourceBergen Drug Corp for ATTRUBY 356 mg tablets (28-count packages) on April 24, 2025, with an ultimate completion date of May 15, 2025. This non-set-aside contract represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX and valued at $999,999,999.00 through December 2026. The pharmaceutical distributor, headquartered...
- The Defense Logistics Agency awarded a $12.78K delivery order to AmerisourceBergen Drug Corp for Attruby 356 mg tablets (28-count units) under a firm fixed-price contract. This non-set-aside award was issued on July 25, 2025, with an ultimate completion date of August 15, 2025. The product will be delivered to AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is a child contract executed under AmerisourceBergen's larger Indefinite Delivery...
- The Defense Logistics Agency awarded a delivery order valued at $25,556.44 to AmerisourceBergen Drug Corp on September 9, 2025, for the supply of Attruby 356 mg tablets (28-count packaging). This is a firm fixed price, non-set-aside competitive delivery order with performance scheduled to conclude by September 30, 2025. The work will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order operates under AmerisourceBergen's larger...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $12,778.22 to AmerisourceBergen Drug Corp for the supply of Attruby 356 mg tablets (28-count package). This firm fixed-price, competitively awarded delivery order was executed on July 28, 2025, with an ultimate completion date of August 18, 2025. The contract will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. No set-aside designation was applied to this award. This delivery...
- The Defense Logistics Agency awarded a $19,134.30 firm fixed-price delivery order to AmerisourceBergen Drug Corp for Attruby 356 mg tablets (28-count) with an ultimate completion date of September 4, 2025. This non-set-aside competitive award represents a child delivery order issued under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), a $999,999,999 global pharmaceutical support vehicle running through December 2026. The place of performance is...
- The Defense Logistics Agency awarded a $12.8K delivery order to AmerisourceBergen Drug Corp on August 25, 2025, for the supply of Attruby 356 mg tablets (28-count packaging). This competitively awarded, firm fixed-price delivery order carries an ultimate completion date of September 16, 2025, and will be performed at the awardee's corporate office location in Conshohocken, Pennsylvania. The contract contains no set-aside designation, reflecting open competition among qualified pharmaceutical...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $38,334.66 to AmerisourceBergen Drug Corp for ATTRUBY 356 mg tablets (28 count) on September 18, 2025, with an ultimate completion date of October 9, 2025. This firm fixed-price delivery order carries no set-aside designation and was competitively awarded. The pharmaceutical supply will be fulfilled from the contractor's location in Conshohocken, Pennsylvania, where AmerisourceBergen maintains its corporate headquarters as a...
- The Defense Logistics Agency awarded a delivery order valued at $12,778.22 to AmerisourceBergen Drug Corp for the supply of Attruby 356 mg tablets (28-count units). This firm fixed-price contract, issued on August 20, 2025, with completion targeted for September 11, 2025, represents a non-set-aside competitive award. The pharmaceutical product will be delivered to the company's facility in Conshohocken, Pennsylvania, where AmerisourceBergen maintains its corporate headquarters as a major...
- The Defense Logistics Agency awarded a delivery order valued at $12,778.22 to AmerisourceBergen Drug Corp for ATTRUBY 356 mg tablets (28-count units) on August 22, 2025, with an ultimate completion date of September 15, 2025. This firm fixed-price delivery order represents a competitive, non-set-aside award to the pharmaceutical distributor's corporate office located in Conshohocken, Pennsylvania. The award is issued under AmerisourceBergen's larger Indefinite Delivery Contract (SPE2DX) with DLA...
- SPE2DB22D1103Indefinite Delivery Contract
- SPE2DB22D1103-SPE2DB25FH2X7Delivery Order
The Defense Logistics Agency awarded a $12.78K delivery order to AmerisourceBergen Drug Corp on September 23, 2025, for the supply of Attruby 356 mg tablets (28-count units) with an ultimate completion date of October 15, 2025. This is a firm fixed-price, competitively awarded contract with no set-aside designation. The award represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), a $1 billion vehicle running through December 2026 that serves as the primary pharmaceutical support mechanism for military healthcare systems globally. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, functions as a critical federal medical vendor supplying a comprehensive range of pharmaceutical products and medical commodities across multiple therapeutic domains to support Defense Health Agency, U.S. Coast Guard, and other government healthcare systems. This delivery order exemplifies AmerisourceBergen's ongoing role as a primary pharmaceutical distributor within the federal medical supply chain. The company's extensive portfolio of federal contract awards demonstrates its capability to fulfill diverse medical procurement requirements through open competition, ranging from small-value transactions to substantial orders. The DLA's Medical Supply Chain continues to leverage this partnership as part of broader federal pharmaceutical acquisition strategies, including the planned Pharmaceutical Prime Vendor Global Program Generation V initiatives that will establish regional contracts with multiple vendors to ensure comprehensive pharmaceutical coverage for military healthcare operations worldwide.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $12.8k | 9/23/25 |